By Fineline Cube ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG: 1541) announced today the dosing of the first patient in its Phase II clinical study evaluating IMM0306, a bispecific antibody (BsAb) targeting CD47 and CD20, for the treatment of systemic lupus erythematosus (SLE).
Clinical Trial Design
| Parameter | Detail |
|---|---|
| Study Phase | II |
| Design | Randomized, placebo-controlled |
| Patient Enrollment | Approximately 90 patients |
| Randomization Ratio | 1:1:1 |
| Treatment Arms | IMM0306 (1.2 mg/kg), IMM0306 (1.6 mg/kg), Placebo |
| Primary Indication | Systemic lupus erythematosus (SLE) |
Drug Profile & Mechanism of Action
- Molecule: Bispecific antibody (BsAb) targeting CD47 and CD20 pathways simultaneously
- Innovation: Novel dual-target approach designed to modulate multiple immune pathways involved in SLE pathogenesis
- Development Status: Currently in Phase II for SLE; also under investigation for IgG4-related disease (IgG4-RD) and primary Sjögren’s syndrome (pSS)
- Intellectual Property: Proprietary bispecific platform owned by ImmuneOnco
Clinical Development Pipeline
| Indication | Development Stage | Status |
|---|---|---|
| Systemic Lupus Erythematosus (SLE) | Phase II | First patient dosed |
| IgG4-Related Disease (IgG4-RD) | Clinical studies | Ongoing |
| Primary Sjögren’s Syndrome (pSS) | Clinical studies | Ongoing |
| Other Autoimmune Conditions | Preclinical/Exploratory | In development |
The company believes that IMM0306’s dual-target mechanism may offer advantages over single-target approaches by simultaneously addressing multiple aspects of the dysregulated immune response characteristic of SLE and related autoimmune disorders.
Market Context & Outlook
- SLE Treatment Landscape: Current therapies often involve broad immunosuppression with significant side effects; targeted biologics represent a growing segment with unmet needs
- Competitive Positioning: IMM0306’s bispecific design differentiates it from existing CD20-only or CD47-only approaches in development
- Commercial Potential: The global SLE therapeutics market is projected to reach $3.5 billion by 2028, with biologics capturing an increasing share
- Regulatory Pathway: Successful Phase II data would support advancement to pivotal Phase III studies, potentially enabling accelerated approval pathways in major markets
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, trial design, and potential therapeutic benefits of IMM0306. Actual results may differ materially due to risks inherent in clinical drug development, including enrollment challenges, safety findings, and efficacy outcomes.-Fineline Info & Tech